If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics should suffice.

Mirador Therapeutics applies machine learning to human data to discover new immunology and inflammation drugs. The startup’s management includes several from the executive team of Prometheus ...

The company has collaboration with Mirador Therapeutics to advance mirador’s precision medicines for immunology and inflammation. 23andMe Holding Co. was founded in 2006 and is headquartered in ...

Yesterday, the company announced a new R&D partnership with precision medicine company Mirador Therapeutics, granting the biotech a license to use a "targeted set of aggregated, de-identified ...

And one startup, Xaira Therapeutics, took it a step further, expanding the industry’s definition of a megaround by reeling in a rarely seen $1 billion financing early in the year. In this week ...

It's got all the hype, but does it have all the money? So far this year, no. As hype continues to swirl around generative AI, the big money--at least in the first quarter of 2024--went not to AI ...